Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2015; 11(5):595-603. doi:10.7150/ijbs.11058 This issue Cite

Research Paper

1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice

Yongxia Yang 1,2, Ying Liu1,2, Lingyun Zheng1, Qianqian Zhang2, Quliang Gu1, Linlin Wang1, Lijing Wang2✉

1. School of Basic Course, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China
2. Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China

✉ Corresponding author: Prof. Lijing Wang: Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China; Tel: 86-(0)20-3935-2126, Fax: 86-(0)20-3935-2126, Email: sheepling-2004com.

Citation:
Yang Y, Liu Y, Zheng L, Zhang Q, Gu Q, Wang L, Wang L. 1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice. Int J Biol Sci 2015; 11(5):595-603. doi:10.7150/ijbs.11058. https://www.ijbs.com/v11p0595.htm
Other styles

File import instruction

Abstract

Graphic abstract

Pancreatic islet β cell tumor is the most common islet cell tumor. A well-characterized tumor progression in Rip1-Tag2 mice undergoes five stages, involving normal, hyperplasia, angiogenic islets, tumorigenesis and invasive carcinoma. 1H NMR based metabonomics was applied to identify potential biomarkers for monitoring pancreatic islet β cell tumor progression in Rip1-Tag2 mice. Multivariate analysis results showed the serum metabonome at hyperplasia stage shared the similar characteristics with the ones at normal stage as a result of slight proliferation of pancreatic islet β cells. At angiogenic islets stage, the up-regulated glycolysis, disturbed choline and phospholipid metabolism composed the metabolic signature. In addition to the changes mentioned above, several metabolites were identified as early biomarkers for tumorigenesis, including increased methionine, citrate and choline, and reduced acetate, taurine and glucose, which suggested the activated energy and amino acid metabolism. All the changes were aggravated at invasive carcinoma stage, coupled with notable changes in alanine, glutamate and glycine. Moreover, the distinct metabolic phenotype was found associated with the implanting of SV40 large T antigen in Rip1-Tag2 mice. The combined metabolic and multivariate statistics approach provides a robust method for screening the biomarkers of disease progression and examining the association between gene and metabolism.

Keywords: 1H NMR, Metabonomics, Pancreatic islet β cell carcinoma, Rip1-Tag2, Serum, Multivariate analysis

Citation styles

APA
Yang, Y., Liu, Y., Zheng, L., Zhang, Q., Gu, Q., Wang, L., Wang, L. (2015). 1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice. International Journal of Biological Sciences, 11(5), 595-603. https://doi.org/10.7150/ijbs.11058.

ACS
Yang, Y.; Liu, Y.; Zheng, L.; Zhang, Q.; Gu, Q.; Wang, L.; Wang, L. 1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice. Int. J. Biol. Sci. 2015, 11 (5), 595-603. DOI: 10.7150/ijbs.11058.

NLM
Yang Y, Liu Y, Zheng L, Zhang Q, Gu Q, Wang L, Wang L. 1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice. Int J Biol Sci 2015; 11(5):595-603. doi:10.7150/ijbs.11058. https://www.ijbs.com/v11p0595.htm

CSE
Yang Y, Liu Y, Zheng L, Zhang Q, Gu Q, Wang L, Wang L. 2015. 1H NMR Based Serum Metabolic Profiles Associated with Pathological Progression of Pancreatic Islet β Cell Tumor in Rip1-Tag2 Mice. Int J Biol Sci. 11(5):595-603.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use